.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The ACTT-2 trial evaluated baricitinib plus remdesivir versus remdesivir alone in hospitalized adults with COVID-19. The combination shortened median recovery time and reduced progression to invasive mechanical ventilation or death in the overall study population. The trial was important for demonstrating that targeted immunomodulation can complement antiviral therapy in patients with systemic inflammatory disease. For internists, the practical lesson is that treatment must match disease stage: antiviral therapy is most useful early in the course, while immunomodulation is considered when inflammatory lung disease or oxygen requirement becomes prominent. Baricitinib requires attention to infection risk, thrombosis and kidney function, and treatment should fit evolving local guidance. The study also illustrates why COVID-19 management moved from a single-drug model toward stage-specific combination therapy. The broader principle applies beyond COVID-19: effective treatment of severe viral disease may require simultaneous control of viral replication and dysregulated host inflammation.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ACTT-2 trial evaluated baricitinib plus remdesivir versus remdesivir alone in hospitalized adults with COVID-19. The combination shortened median recovery time and reduced progression to invasive mechanical ventilation or death in the overall study population. The trial was important for demonstrating that targeted immunomodulation can complement antiviral therapy in patients with systemic inflammatory disease. For internists, the practical lesson is that treatment must match disease stage: antiviral therapy is most useful early in the course, while immunomodulation is considered when inflammatory lung disease or oxygen requirement becomes prominent. Baricitinib requires attention to infection risk, thrombosis and kidney function, and treatment should fit evolving local guidance. The study also illustrates why COVID-19 management moved from a single-drug model toward stage-specific combination therapy. The broader principle applies beyond COVID-19: effective treatment of severe viral disease may require simultaneous control of viral replication and dysregulated host inflammation.
3 weeks back
Discover how catalytic nanozymes redefine autoimmune disease therapy by establishing a physiological redox set-point to restore immune tolerance without broad immunosuppression.
Last week
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
3 weeks back
A landmark comparative study evaluates atrial electrophysiology across humans, swine, and rodents. By linking cellular recordings with transcriptomics and in silico modeling, researchers resolve cross-species gaps, explaining translational failures to advance targeted therapies for atrial arrhythmias.
3 weeks back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
last month
Researchers have developed an innovative ultrasound-responsive nano-contrast agent that co-delivers CIITA-siRNA and rapamycin directly to inflamed thyroid tissue, significantly reducing autoimmune injury and thyroid autoantibodies in preclinical models of Hashimoto thyroiditis.
3 weeks back
